Nicholas Investment Partners LP Invests $2.73 Million in Janux Therapeutics, Inc. (NASDAQ:JANX)

Nicholas Investment Partners LP bought a new position in Janux Therapeutics, Inc. (NASDAQ:JANX) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 50,958 shares of the company’s stock, valued at approximately $2,728,000. Nicholas Investment Partners LP owned 0.10% of Janux Therapeutics at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the company. RA Capital Management L.P. boosted its position in shares of Janux Therapeutics by 13.1% during the fourth quarter. RA Capital Management L.P. now owns 10,365,652 shares of the company’s stock worth $554,977,000 after buying an additional 1,200,000 shares during the period. Janus Henderson Group PLC boosted its position in Janux Therapeutics by 41.2% during the 4th quarter. Janus Henderson Group PLC now owns 3,562,402 shares of the company’s stock worth $190,617,000 after acquiring an additional 1,038,996 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its position in Janux Therapeutics by 47.6% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,061,750 shares of the company’s stock worth $163,926,000 after acquiring an additional 986,750 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Janux Therapeutics by 596.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,109,978 shares of the company’s stock worth $59,429,000 after acquiring an additional 950,557 shares in the last quarter. Finally, FMR LLC raised its holdings in shares of Janux Therapeutics by 10.8% in the fourth quarter. FMR LLC now owns 8,669,941 shares of the company’s stock valued at $464,189,000 after purchasing an additional 845,266 shares during the last quarter. Institutional investors own 75.39% of the company’s stock.

Insider Activity at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 3,334 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $32.15, for a total value of $107,188.10. Following the transaction, the insider now owns 82,139 shares of the company’s stock, valued at approximately $2,640,768.85. This represents a 3.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Ra Capital Management, L.P. purchased 110,206 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The shares were purchased at an average cost of $31.02 per share, with a total value of $3,418,590.12. Following the completion of the acquisition, the director now owns 10,141,287 shares in the company, valued at $314,582,722.74. The trade was a 1.10% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 10,001 shares of company stock worth $313,964. Insiders own 8.10% of the company’s stock.

Wall Street Analysts Forecast Growth

JANX has been the subject of a number of analyst reports. Scotiabank decreased their target price on shares of Janux Therapeutics from $62.00 to $41.00 and set a “sector perform” rating for the company in a research report on Friday, February 28th. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 target price on shares of Janux Therapeutics in a research report on Monday, March 3rd. Finally, Wedbush reissued an “outperform” rating and set a $76.00 price target (up from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $95.25.

Janux Therapeutics Trading Down 2.8%

Shares of NASDAQ JANX opened at $25.33 on Wednesday. The company has a market capitalization of $1.50 billion, a P/E ratio of -21.65 and a beta of 3.24. Janux Therapeutics, Inc. has a 12 month low of $22.52 and a 12 month high of $71.71. The stock has a 50 day moving average of $29.06 and a 200-day moving average of $41.29.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.05. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Analysts predict that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.